Literature DB >> 20669315

Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia.

Simon Zhornitsky1, Emmanuel Stip, Tania Pampoulova, Elie Rizkallah, Olivier Lipp, Lahcen Aït Bentaleb, Jean-Pierre Chiasson, Stéphane Potvin.   

Abstract

Extrapyramidal symptoms (EPS) such as parkinsonism, dystonia, dyskinesia, and akathisia are conditions of impaired motor function, which are associated with chronic antipsychotic treatment in schizophrenia. In addition, EPS is often exacerbated by psychoactive substance (PAS) abuse, which is frequently observed in this population. Few studies, however, have investigated the contribution of PAS abuse on EPS in PAS-abusers without comorbid psychosis. This study compared the occurrence of EPS in outpatient schizophrenia patients with (DD group; n= 36) and without PAS abuse (SCZ group; n = 41) as well as in nonschizophrenia PAS abusers undergoing detoxification [substance use disorder (SUD) group; n = 38]. Psychiatric symptoms were measured using the Positive and Negative Syndrome Scale and the Calgary Depression Scale for schizophrenia. Extrapyramidal symptoms were evaluated with the Extrapyramidal Symptoms Rating Scale and the Barnes Akathisia Scale. SUD diagnoses were complemented with urine drug screenings. We found that DD patients exhibited significantly more parkinsonism than SCZ patients. Our subanalyses revealed that cocaine and alcohol abuse/dependence was responsible for the increase in parkinsonism in DD patients. Additionally, we found that SUD individuals exhibited significantly more akathisia than SCZ patients. In these latter individuals, subanalyses revealed that alcohol and cannabis abuse/dependence was responsible for the increase in akathisia. Our results suggest that PAS abuse is a contributor to EPS in individuals with and without schizophrenia.

Entities:  

Mesh:

Year:  2010        PMID: 20669315     DOI: 10.1002/mds.23227

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  8 in total

1.  Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case-Control Trial with Quetiapine.

Authors:  Simon Zhornitsky; Emmanuel Stip; Joelle Desfossés; Tania Pampoulova; Elie Rizkallah; Pierre-Paul Rompré; Lahcen Aït Bentaleb; Olivier Lipp; Jean-Pierre Chiasson; Alain Gendron; Stéphane Potvin
Journal:  Front Psychiatry       Date:  2011-05-13       Impact factor: 4.157

2.  Antipsychotic-induced parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders.

Authors:  Stéphane Potvin; Ginette Aubin; Emmanuel Stip
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-06-13       Impact factor: 5.270

3.  Cognitive dysfunction and cerebral volumetric deficits in individuals with Alzheimer's disease, alcohol use disorder, and dual diagnosis.

Authors:  Simon Zhornitsky; Shefali Chaudhary; Thang M Le; Yu Chen; Sheng Zhang; Stéphane Potvin; Herta H Chao; Christopher H van Dyck; Chiang-Shan R Li
Journal:  Psychiatry Res Neuroimaging       Date:  2021-08-29       Impact factor: 2.376

4.  Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.

Authors:  Maria Juncal-Ruiz; Mariluz Ramirez-Bonilla; Jorge Gomez-Arnau; Victor Ortiz-Garcia de la Foz; Paula Suarez-Pinilla; Obdulia Martinez-Garcia; Karl David Neergaard; Rafael Tabares-Seisdedos; Benedicto Crespo-Facorro
Journal:  Psychopharmacology (Berl)       Date:  2017-05-31       Impact factor: 4.530

5.  Predictors of community functioning in schizophrenia and substance use disorder patients.

Authors:  Simon Zhornitsky; Ginette Aubin; Joelle Desfossés; Elie Rizkallah; Tania Pampoulova; Olivier Lipp; Jean-Pierre Chiasson; Emmanuel Stip; Stéphane Potvin
Journal:  Community Ment Health J       Date:  2012-07-31

6.  Psychomotor Symptoms in Chronic Cocaine Users: An Interpretative Model.

Authors:  Davide Cenci; Manuel Glauco Carbone; Camilla Callegari; Icro Maremmani
Journal:  Int J Environ Res Public Health       Date:  2022-02-08       Impact factor: 3.390

7.  Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review.

Authors:  Simon Zhornitsky; Emmanuel Stip
Journal:  Schizophr Res Treatment       Date:  2012-02-15

8.  Is the deficit in pain inhibition in fibromyalgia influenced by sleep impairments?

Authors:  Emilie Paul-Savoie; Serge Marchand; Mélanie Morin; Patricia Bourgault; Nathalie Brissette; Vongmaly Rattanavong; Christian Cloutier; Alain Bissonnette; Stéphane Potvin
Journal:  Open Rheumatol J       Date:  2012-10-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.